Loss of Heterozygosity Recruiting Phase 2 Trials for Rucaparib (DB12332)

IndicationStatusPhase
DBCOND0117657 (Loss of Heterozygosity)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03845296Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Treatment